U.S. FDA Accepts Resubmission for ND0612, an Investigational Treatment for Motor Fluctuations in Parkinson’s Disease
  • May 29, 2025
サブ-ナビゲーション
  • Tanabe Pharma Corporation
  • Connecting to Hope
  • About Us
  • 現在位置:News
  • R&D
  • Sustainability
  • Terms of Use
  • Privacy Policy
  • Site Map
  • Contact Us
  • About RSS

U.S. FDA Accepts Resubmission for ND0612, an Investigational Treatment for Motor Fluctuations in Parkinson’s Disease

  • May 29, 2025

Tanabe Pharma issues its news to provide stakeholders with the latest information related to the Company. Information on products or drug candidates may be included, but is intended to provide for the media, etc. It is not intended for promotion, advertising or medical advice. Information is current as of the date of issue of the individual news. Please be advised that information may be outdated after that point.

VIEW ALL

  • header-content
  • header-content

  • CLOSE
  • MENU

Site Search

If you agree to the use of cookies, please click the "Agree" button.
If you do not agree, please do not use this site. For details, please refer to the following page.

Privacy Policy

Agree

URL
 

田辺ファーマ株式会社のサイトを離れます。よろしいですか?
(別ウィンドウが開きます)

You are leaving the Tanabe Pharma Corporation’s website.
(A new window will be opened.)

はい / O.K.
いいえ / Cancel
  • footer-content